ORIC Pharmaceuticals Ownership | Who Owns ORIC Pharmaceuticals?
ORIC Pharmaceuticals Ownership Summary
ORIC Pharmaceuticals is owned by 14.37% institutional investors, 9.50% insiders, and 76.13% retail investors. Pfizer is the largest institutional shareholder, holding 7.62% of ORIC shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.65% of its assets in ORIC Pharmaceuticals shares.
ORIC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | ORIC Pharmaceuticals | 14.37% | 9.50% | 76.13% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Pfizer | 5.38M | 7.62% | $43.39M |
| Nextech invest | 5.29M | 7.49% | $42.66M |
| Blackrock funding, inc. /de | 5.11M | 7.25% | $41.26M |
| Blackrock | 4.83M | 7.17% | $34.15M |
| Viking global investors lp | 4.43M | 6.28% | $35.76M |
| Vr adviser | 4.39M | 6.23% | $35.46M |
| Frazier life sciences management | 4.14M | 6.15% | $29.29M |
| Alkeon capital management | 3.90M | 5.53% | $31.51M |
| Column group | 3.54M | 5.02% | $28.57M |
| Ecor1 capital | 3.42M | 4.85% | $27.58M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Column group | 3.54M | 51.26% | $28.57M |
| Superstring capital management lp | 1.58M | 11.05% | $12.76M |
| Invus financial advisors | 1.01M | 7.98% | $7.12M |
| Nextech invest | 5.29M | 6.92% | $42.66M |
| Vr adviser | 4.39M | 2.43% | $35.46M |
| First turn management | 1.45M | 2.10% | $11.71M |
| Silverarc capital management | 1.18M | 2.08% | $9.51M |
| Pfizer | 5.38M | 1.67% | $43.39M |
| Frazier life sciences management | 4.14M | 1.37% | $29.29M |
| Commodore capital lp | 2.00M | 1.18% | $16.14M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Pfizer | 5.38M | 1.67% | 5.38M |
| Blackrock | 4.83M | 0.00% | 1.65M |
| Schonfeld strategic advisors | 724.32K | 0.03% | 724.32K |
| Superstring capital management lp | 1.58M | 11.05% | 631.22K |
| State street | 2.26M | 0.00% | 540.15K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 2.47M | 0.00% | -1.91M |
| Orbimed advisors | - | - | -287.10K |
| Millennium management | 27.63K | 0.00% | -265.89K |
| Nicholas investment partners, lp | - | - | -183.49K |
| Avidity partners management lp | 1.27M | 1.00% | -181.92K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Pfizer | 5.38M | 1.67% | 5.38M | $43.39M |
| Schonfeld strategic advisors | 724.32K | 0.03% | 724.32K | $5.85M |
| Hudson bay capital management lp | 120.00K | 0.00% | 120.00K | $968.40K |
| Natixis | 79.90K | 0.00% | 79.90K | $644.79K |
| Neos investment management | 45.48K | 0.01% | 45.48K | $366.99K |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -1.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Nbc securities | -118.00 |
| Bessemer group | -120.00 |
| Federated hermes | -152.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 39 | -68.29% | 10,134,721 | -85.49% | 14 | 0.15% | 26 | -58.06% | 7 | -81.58% |
| Sep 30, 2024 | 123 | 10.81% | 69,828,652 | 3.33% | 98 | 0.98% | 62 | -16.22% | 38 | 100.00% |
| Jun 30, 2024 | 111 | -2.63% | 67,581,249 | 5.85% | 100 | 1.12% | 74 | 10.45% | 19 | -32.14% |
| Mar 31, 2024 | 114 | 20.00% | 63,846,117 | 26.08% | 94 | 1.22% | 67 | 17.54% | 28 | 40.00% |
| Dec 31, 2023 | 95 | 4.40% | 50,638,927 | 5.41% | 88 | 1.26% | 57 | 39.02% | 20 | -28.57% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.88M | 2.65% | - |
| Vanguard US Total Market Shares ETF | 1.88M | 2.65% | - |
| iShares Russell 2000 ETF | 1.59M | 2.24% | -13.80K |
| Fidelity Growth Compy Commingled Pl S | 1.31M | 1.84% | 1.39K |
| Fidelity Growth Compy Commingled Pl O | 1.28M | 1.81% | - |
| T. Rowe Price Health Sciences | 973.19K | 1.37% | - |
| SPDR® S&P Biotech ETF | 948.52K | 1.34% | -10.15K |
| Fidelity Growth Company Fund | 725.73K | 1.02% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 715.04K | 1.01% | 1.21K |
| Franklin Biotechnology Discv A(acc)USD | 638.19K | 0.90% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 16, 2024 | Piscitelli Dominic | Chief Financial Officer | Sell | $73.30K |
| Dec 16, 2024 | Multani Pratik S | Chief Medical Officer | Sell | $73.29K |
| Dec 16, 2024 | Chacko Jacob | PRESIDENT AND CEO | Sell | $204.21K |
| Mar 06, 2024 | Chacko Jacob | PRESIDENT AND CEO | Sell | $648.38K |
| Feb 07, 2024 | Chacko Jacob | PRESIDENT AND CEO | Sell | $320.19K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | - |
| 2024 Q4 | - | 3 |
| 2024 Q2 | - | - |
| 2024 Q1 | - | 3 |
| 2023 Q4 | - | 3 |
ORIC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools